Are you the publisher? Claim or contact us about this channel


Embed this content in your HTML

Search

Report adult content:

click to rate:

Account: (login)

More Channels


Channel Catalog


Channel Description:

Daily news and press releases about Healthcare

older | 1 | .... | 1030 | 1031 | (Page 1032) | 1033 | 1034 | .... | 1118 | newer

    0 0

    (EMAILWIRE.COM, May 05, 2018 ) About the market report:

    GlobalData’s new report, North America Immuno Chemistry Market Outlook to 2024, provides key market data on the North America Immuno Chemistry market. The report provides value, in millions of US dollars, volume (in units) and average prices (USD) within market segments-Complement Deficiency Tests, Diabetes Assays, Disease Specific Immunochemistry, Endocrinology Tests, IgE Allergy Blood Tests, Immunochemistry Analyzers, Immunochemistry Rapid Tests & POC and Vitamins Tests

    The report also provides company shares and distribution shares data for each of these market segments, and global corporate-level profiles of the key market participants. Based on the availability of data for the particular market and country, information related to pipeline products, news and deals is available in the report.

    To access the full table of contents of the report click below:
    Link to the table of contents: “https://www.marketintelreports.com/report/gd2118/north-america-immuno-chemistry-market-outlook-to-2024”


    Scope of the Report:

    - Market size and company share data for Immuno Chemistry market segments - Complement Deficiency Tests, Diabetes Assays, Disease Specific Immunochemistry, Endocrinology Tests, IgE Allergy Blood Tests, Immunochemistry Analyzers, Immunochemistry Rapid Tests & POC and Vitamins Tests.
    - Annualized market revenues (USD million) and volume (units) data for each of the market segments. Data is provided from 2010 to 2017 and forecast to 2024.
    - 2017 company shares and distribution shares data for each of the market segments.
    - Global corporate-level profiles of key companies operating within the North America Immuno Chemistry market.

    There are 10 Chapters to deeply display the North America Immuno Chemistry market.

    To find out more of the report or request some customization :
    Link to the Inquiry before purchase: “https://www.marketintelreports.com/inquiry-before-buying.php?id=gd2118”

    Table of Contents-Key Points Covered – Partial paste
    1 Table of Contents
    1 Table of Contents 2
    1.1 List of Tables 4
    1.2 List of Figures 7
    2 Introduction 10
    2.1 What Is This Report About? 10
    2.2 Immuno Chemistry Market Segmentation 10
    2.3 Definitions of Markets Covered in the Report 12
    3 Immuno Chemistry Market, North America 16
    3.1 Immuno Chemistry Market, North America, Revenue ($m), 2010-2024 16
    3.2 Immuno Chemistry Market, North America, Category Comparison by Revenue ($m), 2010-2024 18
    3.3 Immuno Chemistry Market, North America, Revenue ($m), 2010-2017 20
    3.4 Immuno Chemistry Market, North America, Revenue ($m), 2017-2024 22
    3.5 Immuno Chemistry Market, North America, Volume (Units), 2010-2024 24
    3.6 Immuno Chemistry Market, North America, Volume (Units), 2010-2017 26
    3.7 Immuno Chemistry Market, North America, Volume (Units), 2017-2024 28
    3.8 Immuno Chemistry Market, North America, Company Share by Revenue ($m), 2017 30
    4 Immuno Chemistry Market, Canada 32
    4.1 Immuno Chemistry Market, Canada, Revenue ($m), 2010-2017 32
    4.2 Immuno Chemistry Market, Canada, Revenue ($m), 2017-2024 34
    4.3 Immuno Chemistry Market, Canada, Volume (Units), 2010-2017 68
    4.4 Immuno Chemistry Market, Canada, Volume (Units), 2017-2024 70
    4.5 Immuno Chemistry Market, Canada, Average Price ($), 2010-2024 104
    4.6 Immuno Chemistry Market, Canada, Distribution Share by Revenue ($m), 2017 108
    4.7 Immuno Chemistry Market, Canada, Company Share by Revenue ($m), 2017 109
    Continued…..

    Complete Report Details @ https://www.marketintelreports.com/report/gd2118/north-america-immuno-chemistry-market-outlook-to-2024

    About us:

    MIR intends to be a one-stop shop with an intuitive design, exhaustive database, expert assistance, secure cart checkout and data privacy integrated. It curates the list of reports, publishers and studies to ensure that the database is constantly updated to dynamically meet the targeted, specific needs of our clients.
    MarketIntelReports currently has more than 2.5 million titles and 200 publishers on our platform and are growing consistently to fill the “World Intelligence Demand – Supply Gap”. We cover more than 15 industry verticals being: Automotive, Electronics, Manufacturing, Pharmaceuticals, Healthcare, Chemicals, Building & Construction, Agriculture, Food & Beverages, Banking & Finance, Media and Government, Public Sector Studies.


    Lakshmi
    1-302-261-5343
    sales@marketintelreports.com

    Source: EmailWire.Com

    0 0

    (EMAILWIRE.COM, May 05, 2018 ) About the market report:

    North America Infectious Diagnostics Market Outlook to 2024, provides key market data on the North America Infectious Diagnostics market. The report provides value, in millions of US dollars, volume (in units) and average prices (USD) within market segments-Bacteriology, Chlamydia trichomatis Diagnostic Test Kits, Cytomegalovirus (CMV) & Herpes simplex Virus (HSV) Tests, Hepatitis Test Kits, Human Papilloma Virus (HPV) & Epstein-Barr Virus (EBV) Tests, Infectious Diagnostics Multiple Parameter Test Kits, Infectious Diagnostics Rapid Tests & POC, Mycobacterium tuberculosis Diagnostic Tests, Nucleic Acid Testing Extraction Instruments, Other Virology, Parasitology & Mycology, Polymerase Chain Reaction (PCR) Systems, Post Streptococcus pyogenes Diagnostic Tests, Retrovirus Tests and Treponema pallidum Diagnostic Tests.

    The report also provides company shares and distribution shares data for each of these market segments, and global corporate-level profiles of the key market participants. Based on the availability of data for the particular market and country, information related to pipeline products, news and deals is available in the report.

    To access the full table of contents of the report click below:
    Link to the table of contents: “https://www.marketintelreports.com/report/gd2119/north-america-infectious-diagnostics-market-outlook-to-2024”


    Scope of the Report:

    - Market size and company share data for Infectious Diagnostics market segments - Bacteriology, Chlamydia trichomatis Diagnostic Test Kits, Cytomegalovirus (CMV) & Herpes simplex Virus (HSV) Tests, Hepatitis Test Kits, Human Papilloma Virus (HPV) & Epstein-Barr Virus (EBV) Tests, Infectious Diagnostics Multiple Parameter Test Kits, Infectious Diagnostics Rapid Tests & POC, Mycobacterium tuberculosis Diagnostic Tests, Nucleic Acid Testing Extraction Instruments, Other Virology, Parasitology & Mycology Polymerase Chain Reaction (PCR) Systems, Post Streptococcus pyogenes Diagnostic Tests, Retrovirus Tests and Treponema pallidum Diagnostic Tests.
    - Annualized market revenues (USD million) and volume (units) data for each of the market segments. Data is provided from 2010 to 2017 and forecast to 2024.

    There are 10 Chapters to deeply display the North America Infectious Diagnostics market.

    To find out more of the report or request some customization:
    Link to the Inquiry before purchase: “https://www.marketintelreports.com/inquiry-before-buying.php?id=gd2119”

    Table of Contents-Key Points Covered – Partial paste
    1 Table of Contents
    1 Table of Contents 2
    1.1 List of Tables 4
    1.2 List of Figures 8
    2 Introduction 13
    2.1 What Is This Report About? 13
    2.2 Infectious Diagnostics Market Segmentation 13
    2.3 Definitions of Markets Covered in the Report 15
    3 Infectious Diagnostics Market, North America 20
    3.1 Infectious Diagnostics Market, North America, Revenue ($m), 2010-2024 20
    3.2 Infectious Diagnostics Market, North America, Category Comparison by Revenue ($m), 2010-2024 22
    3.3 Infectious Diagnostics Market, North America, Revenue ($m), 2010-2017 24
    3.4 Infectious Diagnostics Market, North America, Revenue ($m), 2017-2024 27
    3.5 Infectious Diagnostics Market, North America, Volume (Units), 2010-2024 30
    3.6 Infectious Diagnostics Market, North America, Volume (Units), 2010-2017 32
    3.7 Infectious Diagnostics Market, North America, Volume (Units), 2017-2024 35
    3.8 Infectious Diagnostics Market, North America, Company Share by Revenue ($m), 2017 38
    4 Infectious Diagnostics Market, Canada 40
    4.1 Infectious Diagnostics Market, Canada, Revenue ($m), 2010-2017 40
    4.2 Infectious Diagnostics Market, Canada, Revenue ($m), 2017-2024 43
    4.3 Infectious Diagnostics Market, Canada, Volume (Units), 2010-2017 90
    4.4 Infectious Diagnostics Market, Canada, Volume (Units), 2017-2024 93
    Continued…..

    Complete Report Details @ https://www.marketintelreports.com/report/gd2119/north-america-infectious-diagnostics-market-outlook-to-2024

    About us:

    MIR intends to be a one-stop shop with an intuitive design, exhaustive database, expert assistance, secure cart checkout and data privacy integrated. It curates the list of reports, publishers and studies to ensure that the database is constantly updated to dynamically meet the targeted, specific needs of our clients.

    MarketIntelReports currently has more than 2.5 million titles and 200 publishers on our platform and are growing consistently to fill the “World Intelligence Demand – Supply Gap”. We cover more than 15 industry verticals being: Automotive, Electronics, Manufacturing, Pharmaceuticals, Healthcare, Chemicals, Building & Construction, Agriculture, Food & Beverages, Banking & Finance, Media and Government, Public Sector Studies.


    Lakshmi
    1-302-261-5343
    sales@marketintelreports.com

    Source: EmailWire.Com

    0 0

    (EMAILWIRE.COM, May 05, 2018 ) About the market report:

    North America Immuno Chemistry Market Outlook to 2024, provides key market data on the North America Immuno Chemistry market. The report provides value, in millions of US dollars, volume (in units) and average prices (USD) within market segments-Complement Deficiency Tests, Diabetes Assays, Disease Specific Immunochemistry, Endocrinology Tests, IgE Allergy Blood Tests, Immunochemistry Analyzers, Immunochemistry Rapid Tests & POC and Vitamins Tests

    The report also provides company shares and distribution shares data for each of these market segments, and global corporate-level profiles of the key market participants. Based on the availability of data for the particular market and country, information related to pipeline products, news and deals is available in the report.

    To access the full table of contents of the report click below:
    Link to the table of contents: “https://www.marketintelreports.com/report/gd2118/north-america-immuno-chemistry-market-outlook-to-2024”


    Scope of the Report:

    - Market size and company share data for Immuno Chemistry market segments - Complement Deficiency Tests, Diabetes Assays, Disease Specific Immunochemistry, Endocrinology Tests, IgE Allergy Blood Tests, Immunochemistry Analyzers, Immunochemistry Rapid Tests & POC and Vitamins Tests.
    - Annualized market revenues (USD million) and volume (units) data for each of the market segments. Data is provided from 2010 to 2017 and forecast to 2024.
    - 2017 company shares and distribution shares data for each of the market segments.
    - Global corporate-level profiles of key companies operating within the North America Immuno Chemistry market.

    There are 10 Chapters to deeply display the North America Immuno Chemistry market.

    To find out more of the report or request some customization :
    Link to the Inquiry before purchase: “https://www.marketintelreports.com/inquiry-before-buying.php?id=gd2118”

    Table of Contents-Key Points Covered – Partial paste
    1 Table of Contents
    1 Table of Contents 2
    1.1 List of Tables 4
    1.2 List of Figures 7
    2 Introduction 10
    2.1 What Is This Report About? 10
    2.2 Immuno Chemistry Market Segmentation 10
    2.3 Definitions of Markets Covered in the Report 12
    3 Immuno Chemistry Market, North America 16
    3.1 Immuno Chemistry Market, North America, Revenue ($m), 2010-2024 16
    3.2 Immuno Chemistry Market, North America, Category Comparison by Revenue ($m), 2010-2024 18
    3.3 Immuno Chemistry Market, North America, Revenue ($m), 2010-2017 20
    3.4 Immuno Chemistry Market, North America, Revenue ($m), 2017-2024 22
    3.5 Immuno Chemistry Market, North America, Volume (Units), 2010-2024 24
    3.6 Immuno Chemistry Market, North America, Volume (Units), 2010-2017 26
    3.7 Immuno Chemistry Market, North America, Volume (Units), 2017-2024 28
    3.8 Immuno Chemistry Market, North America, Company Share by Revenue ($m), 2017 30
    4 Immuno Chemistry Market, Canada 32
    4.1 Immuno Chemistry Market, Canada, Revenue ($m), 2010-2017 32
    4.2 Immuno Chemistry Market, Canada, Revenue ($m), 2017-2024 34
    4.3 Immuno Chemistry Market, Canada, Volume (Units), 2010-2017 68
    4.4 Immuno Chemistry Market, Canada, Volume (Units), 2017-2024 70
    4.5 Immuno Chemistry Market, Canada, Average Price ($), 2010-2024 104
    4.6 Immuno Chemistry Market, Canada, Distribution Share by Revenue ($m), 2017 108
    4.7 Immuno Chemistry Market, Canada, Company Share by Revenue ($m), 2017 109
    Continued…..

    Complete Report Details @ https://www.marketintelreports.com/report/gd2118/north-america-immuno-chemistry-market-outlook-to-2024

    About us:

    MIR intends to be a one-stop shop with an intuitive design, exhaustive database, expert assistance, secure cart checkout and data privacy integrated. It curates the list of reports, publishers and studies to ensure that the database is constantly updated to dynamically meet the targeted, specific needs of our clients.
    MarketIntelReports currently has more than 2.5 million titles and 200 publishers on our platform and are growing consistently to fill the “World Intelligence Demand – Supply Gap”. We cover more than 15 industry verticals being: Automotive, Electronics, Manufacturing, Pharmaceuticals, Healthcare, Chemicals, Building & Construction, Agriculture, Food & Beverages, Banking & Finance, Media and Government, Public Sector Studies.


    Lakshmi
    1-302-261-5343
    sales@marketintelreports.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, May 07, 2018 ) According to a new market research report Dermatology Devices Market by Diagnostic Device (Imaging Device, Dermatoscope, Microscope), Treatment Device (Electrosurgical, Cryotherapy, Laser), Application (Skin Cancer Diagnosis, Acne, Psoriasis, Skin Rejuvenation, Warts) - Global Forecasts to 2021", published by MarketsandMarkets, the global market is expected to reach USD 14.17 Billion by 2021 from USD 8.22 Billion in 2016, at a CAGR of 11.50% during the forecast period.

    The rising incidence of skin disorders, increasing awareness on aesthetic procedures, technological advancements, and increasing healthcare expenditure are the major factors driving the growth of this market.

    The global Dermatology Devices Market is segmented into diagnostic devices (by type and application) and treatment devices (by type and application). Based on the type of diagnostic devices, the Dermatology Devices Market is segmented into dermatoscopes, microscopes, and imaging devices. The imaging devices segment is expected to account for the largest share of the market during the forecast period. The large share of this segment can be attributed to technological advancements and increasing awareness about the available aesthetic procedures in the market.

    Download Free PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=154

    On the basis of the type of treatment devices, the Dermatology Devices Market is segmented into light therapy devices, lasers, electrosurgical equipment, liposuction devices, microdermabrasion devices, and cryotherapy devices. In 2016, the light therapy devices segment is expected to account for the largest share primarily due to the increasing incidence of skin diseases and technological advancements.

    On the basis of the application of diagnostic devices, the Dermatology Devices Market is segmented into skin cancer diagnosis and other diagnostic applications. The skin cancer diagnosis segment is expected to account for the largest share in 2016. The rising incidence of skin disorders is the major factor driving the growth of this market.

    On the basis of the application of treatment devices, the Dermatology Devices Market is segmented into hair removal; skin rejuvenation; acne, psoriasis, and tattoo removal; wrinkle removal and skin resurfacing; body contouring and fat removal; vascular and pigmented lesion removal; warts, skin tags, and weight management; and other treatment applications. The other treatment applications segment is expected to account for the largest share of the market during the forecast period, primarily due to the increasing awareness about aesthetic procedures and technological advancements.

    Based on region, the global Dermatology Devices Market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). Asia is expected to grow at the highest CAGR during the forecast period. Growth in this regional segment is driven by factors such as the rising incidence of skin diseases, increasing healthcare expenditure, and increasing awareness regarding aesthetic procedures.

    Some of the major players operating in the Dermatology Devices Market are Alma Lasers, Ltd. (Israel), Cutera, Inc. (U.S.), Cynosure, Inc. (U.S.), Lumenis, Ltd. (Israel), and Valeant Pharmaceuticals International, Inc. (Canada).

    Contact:
    Mr. Rohan
    MarketsandMarkets™ INC.
    630 Dundee Road
    Suite 430
    Northbrook, IL 60062
    USA : 1-888-600-6441
    sales@marketsandmarkets.com


    Mr. Rohan
    1-888-600-6441
    sales@marketsandmarkets.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, May 07, 2018 ) According to a new market research report "Healthcare Integration Market by Product (Interface Engine, Medical Device Integration, Media Integration), by Service (Implementation, Support, Training), by Application (Hospital, Laboratory, Radiology, Clinics) - Global Forecast to 2021", published by MarketsandMarkets, The global market is expected to reach USD 3.73 Billion by 2021 from USD 2.30 Billion in 2016, at a CAGR of 10.2% from 2016 to 2021.

    The market analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Europe, Asia-Pacific, and the Rest of the world (RoW).

    Download FREE Brochure: https://www.marketsandmarkets.com/pdfdownload.asp?id=228536178

    The healthcare IT integration market recorded a healthy growth rate during the last decade, owing to technological advancements and increasing adoption of healthcare IT integration systems among healthcare providers across globe. Healthcare IT integrations are used extensively in several applications, including hospital integration, medical device integration, lab integration, clinics integration, radiology integration, and other applications. The rising EHR adoption, growing need to integrate healthcare systems, and efforts from healthcare providers to maximize their returns on investment are expected to have a positive impact on the growth of this market in the coming years. This trend is expected to support the growth of the market in the coming years.

    In this report, the global healthcare IT integration market is segmented based on solutions, applications, and geographic regions. Based on solutions, the market is segmented into products and services. The healthcare integration products market is further divided into interface/integration engines, medical device integration software, media integration solutions, and other integration tools. On the basis of services, the market is segmented into implementation services, support and maintenance services, and training services.

    On the basis of regions, the market is further divided into North America, Europe, Asia-Pacific, and Rest of the World (RoW). In 2015, North America accounted for the largest share of the global healthcare IT integration market, followed by Europe and Asia-Pacific. Greater uptake of healthcare IT integration systems and the presence of a large number of healthcare IT integration solutions manufacturers in North America and Europe are the major factors responsible for the large shares of these regions in the market. However, the Asia-Pacific region is expected to offer significant growth opportunities for players operating in the healthcare IT integration market in the coming years. The high growth in this regional segment is primarily driven by factors such as growing healthcare awareness, growth in geriatric population, less stringent regulations, increasing investments in the APAC healthcare industry by key market players, rising healthcare infrastructure, and increased demand for quality care.

    The prominent players in the global healthcare IT integration market include Infor, Inc. (U.S.), InterSystems Corporation (U.S.), Cerner Corporation (U.S.), Orion Health (New Zealand), Quality Systems, Inc. (U.S.), Interfaceware, Inc. (Canada), Allscripts Healthcare Solutions, Inc. (U.S.), Epic Systems Corporation (U.S.), Qualcomm Life, Inc. (U.S.), AVI-SPL, Inc. (U.S.), Corepoint Health (U.S.), and Oracle Corporation (U.S.).

    Contact:
    Mr. Rohan
    MarketsandMarkets™ INC.
    630 Dundee Road
    Suite 430
    Northbrook, IL 60062
    USA : 1-888-600-6441
    sales@marketsandmarkets.com


    Mr. Rohan
    1-888-600-6441
    sales@marketsandmarkets.com

    Source: EmailWire.Com

    0 0

    (EMAILWIRE.COM, May 05, 2018 ) Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Sinuscopes Endoscope Sales in these regions, from 2013 to 2025 (forecast), covering
    • North America
    • Europe
    • China
    • Japan
    • Southeast Asia
    • India
    Access Report Details at: https://www.themarketreports.com/report/global-sinuscopes-endoscope-sales-market-report-2018
    Global Sinuscopes Endoscope Sales market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including
    • Amd Global Telemedicine (Usa)
    • Anetic Aid (Uk)
    • Asap Endoscopic Products (Germany)
    • Emos Technology (Germany)
    • Endoservice Optical Instruments (Germany)
    • Entermed (Netherlands)
    • Gaes Medical (Spain)
    • Henke-Sass, Wolf (Germany)
    • Locamed (Uk)
    • Maxer Endoscopy (Germany)
    • Medstar (Usa)
    • Msi - Medserv International (Germany)
    • Optim Llc (Usa)
    • Optomic (Spain)
    • Schindler Endoskopie Technologie (Germany)
    • Scholly Fiberoptic Gmbh (Germany)
    • Sopro-Comeg (France)
    • Vimex Endoscopy (Poland)
    Purchase this Premium Report at: https://www.themarketreports.com/report/buy-now/1109080
    On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
    • Straight
    • Semi-flexible
    • Bent
    On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate of Sinuscopes Endoscope Sales for each application, including
    • Hospital
    • Clinic
    • Others
    Inquire about this Report at: https://www.themarketreports.com/report/ask-your-query/1109080


    Shirish Gupta
    +1-631-407-1315
    web@themarketreports.com

    Source: EmailWire.Com

    0 0

    (EMAILWIRE.COM, May 05, 2018 ) About Report:
    The increased adoption of medical robots in hospitals and pharmaceuticals, the growing ageing population, and the increasing patients’ preference for minimally invasive surgeries are forcing organizations to focus on developing innovative solutions. The increasing demand for managed care and shortage of professionals in the healthcare domain are some of the additional factors contributing to the market growth. The Medical Robots Market is expected to reach $17.58 billion by 2023, growing at a CAGR of 22.0% during the forecast period 2017–2023.

    Product Analysis:

    The products segment holds a prominent market share and is expected to reach $17.58 billion by 2023. A number of start-ups are entering the market to offer attractive designs and innovative features in medical robots to the customers. IoT innovations and the increasing R&D investments from big organizations for enhancement of their product portfolio are also contributing to the market growth.

    To access the full table of contents of the report click below:
    Link to the table of contents: https://www.marketintelreports.com/report/ihr0003/medical-robots-market--global-drivers-restraints-opportunities-trends-and-forecasts-to-2023

    Regional Analysis:

    Currently, North America has a majority share of the Medical Robots Market mainly due to technology advancements. The Medical Robots Market is witnessing a strong growth in countries such as the US and Canada. Europe is spending heavily in the manufacturing of innovative solutions for medical robots. The developing regions, such as Asia Pacific, is expected to improve its market share during the forecast period.
    The regional government initiatives for developing smart city projects and the increasing FDI for the development of digital healthcare infrastructure in the regions are the main factors contributing to the market growth. MEA is expected to experience a strong market as the regional governments are spending generously on infrastructural developments which will create huge opportunities for the key players to provide innovative solutions in the region


    Competitive Analysis:
    The study covers and analyzes the Medical Robots market. Bringing out the complete key insights of the industry, the report aims to provide an opportunity for players to understand the latest trends, current market scenario, government initiatives, and technologies related to the market. In addition, it helps the venture capitalists in understanding the companies better and take informed decisions.
    To find out more of the report or request some customization:
    Link to the Inquiry before purchase: https://www.marketintelreports.com/inquiry-before-buying.php?id=ihr0003


    Key Players:

    The key players covered in the report are Medtronic, Stryker, Intuitive Surgical, Boston Scientific, Mazor Robotics, BALT Extrusion, Cyberonics, and Ekso Bionics.

    Table of contents
    1 Industry Outlook
    1.1 Industry Overview
    1.2 Industry Trends
    1.3 PEST Analysis
    2 Report Outline
    2.1 Report Scope
    2.2 Report Summary
    2.3 Research Methodology
    2.4 Report Assumptions
    3 Market Snapshot
    3.1 Total Addressable Market
    3.2 Segmented Addressable Market
    3.3 Related Markets
    3.3.1 AI in Healthcare
    3.3.2 Industrial Robotics
    4 Market Outlook
    4.1 Overview
    4.2 Market Trends
    4.3 Market Definition – Infoholic Research
    4.4 Porter 5 (Five) Forces
    5 Market Characteristics
    5.1 Medical Robots: Advantages and Disadvantages
    5.2 Evolution of Robot Assisted Surgery
    5.3 Market Segmentation
    5.4 Market Dynamics
    5.4.1 Drivers
    5.4.1.1 Benefits of robot assisted training in rehabilitation therapy
    5.4.1.2 Technological advancements
    5.4.1.3 Increasing funding on R&D
    5.4.1.4 Increasing investments from hospitals
    5.4.2 Restraints
    5.4.2.1 Safety concerns over robotic surgery devices
    5.4.2.2 High cost
    5.4.3 Opportunities
    5.4.3.1 Rapid growth in aging population
    5.4.3.2 Huge opportunities for nanorobots makers
    5.4.3.3 Increasing demand from patients for minimally invasive surgeries
    5.5 DRO – Impact Analysis
    5.6 Key Stakeholders
    6 Products: Market Size and Analysis
    6.1 Overview
    6.2 Instruments and Accessories
    6.3 Medical Robotic Systems
    6.3.1 Market Size and Analysis
    6.3.2 Surgical Robots
    6.3.2.1 Laparoscopy Robotic Systems
    6.3.2.2 Neurosurgical Robotic Systems
    6.3.2.3 Orthopedic Robotic Systems
    6.3.2.4 Steerable Robotic Catheters
    6.3.3 Rehabilitation Robotic Systems
    6.3.3.1 Therapeutic Robotic Systems
    6.3.3.2 Assistive Robotic Systems
    6.3.3.3 Prosthetic Robotic Systems
    6.3.3.4 Orthotic Robotic Systems
    6.3.3.5 Exoskeleton Robotic Systems
    6.3.4 Non-invasive Radiosurgery Robotic Systems
    6.3.5 Hospital and Pharmacy Robotic Systems
    6.3.5.1 Pharmacy Robotic Systems
    6.3.5.2 IV Robotic Systems
    6.3.5.3 Telemedicine Robots
    6.3.6 Other Robotic Systems
    7 Applications by Surgical Areas: Market Size and Analysis
    7.1 Overview
    7.2 Laparoscopy
    7.2.1 Market Size and Analysis
    7.3 Orthopedics
    7.3.1 Market Size and Analysis
    7.4 Neurology
    7.4.1 Market Size and Analysis
    7.5 Special Education
    7.5.1 Market Size and Analysis
    7.6 Others
    7.6.1 Market Size and Analysis
    Continued......................

    Complete Report with Details @ https://www.marketintelreports.com/report/ihr0003/medical-robots-market--global-drivers-restraints-opportunities-trends-and-forecasts-to-2023

    About us:
    MIR intends to be a one-stop shop with an intuitive design, exhaustive database, expert assistance, secure cart checkout and data privacy integrated. It curates the list of reports, publishers and studies to ensure that the database is constantly updated to dynamically meet the targeted, specific needs of our clients.
    MarketIntelReports currently has more than 2.5 million titles and 200 publishers on our platform and are growing consistently to fill the “World Intelligence Demand – Supply Gap”. We cover more than 15 industry verticals being: Automotive, Electronics, Manufacturing, Pharmaceuticals, Healthcare, Chemicals, Building & Construction, Agriculture, Food & Beverages, Banking & Finance, Media and Government, Public Sector Studies.


    Lakshmi
    1-302-261-5343
    sales@marketintelreports.com

    Source: EmailWire.Com

    0 0

    (EMAILWIRE.COM, May 05, 2018 ) Singapore -- Market Report on Global Aortic Aneurysm

    Aortic aneurysm is a condition in which the aortic wall is enlarged at a certain point, which leads to rupturing of the artery resulting in internal bleeding. Abdominal aortic aneurysm (AAA) and thoracic aortic aneurysm (TAA) are the two types of aneurysms based on the location of the aneurysm.

    The first AAA surgical procedure was performed in 1991 and since then there has been an evolution in the treatment of stent grafts. Montenegro, Armenia, and New Zealand were the top three regions with highest mortality rate in 2013.The Global Aortic Aneurysm Market is estimated to witness a CAGR of 6.6% during the forecast period 2017–2023.The aortic aneurysm market is analyzed based on three segments – type, product types, and regions.

    To access the full table of contents of the report click below:
    Link to the table of contents:https://www.marketintelreports.com/report/ihr0007/worldwide-aortic-aneurysm-market-trends-and-drivers-restraints-and-opportunities-20172023

    Regional Analysis:

    The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (ROW). North America is set to be the leading region for the aortic aneurysm market growth followed by Europe. Asia Pacific and ROW are set to be the emerging regions. Japan is the second standalone market after the US growing with a double digit CAGR.


    Analysis by Types:

    The aortic aneurysm market is segmented into AAA and TAA. AAA occupies the major share in the market with EVAR being the most adopted AAA procedure. TAA is the fastest growing segment in the market. This is due to the technological advancements and the increasing awareness of the condition among the patients globally.


    Analysis by Product Types:

    Based on products, the market is segmented as stent grafts, catheters, and other accessories. The stent grafts segment held the major share in 2016, and is expected to grow at a rate of 6.75% during the forecast period. Among the types of stent grafts, AAA stent grafts held a major share in 2016, and the rest of the market is held by TAA stent grafts.

    Scope:

    The report provides complete details about the usage and adoption rate of aortic aneurysm repair devices in various verticals and regions. These help the key stakeholders to know about the major trends, drivers, investments, and vertical player’s initiatives in the upcoming years. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in specific verticals, and to analyze before investing or expanding the business in this market.


    Key Players:

    Cook Medical’s Medtronic PLC, W.L.Gore & Associates, MicroPort Scientific Corporation, Terumo Corporation, Endologix, Jotec GmbH, Boston Scientific Corporation, and other predominant and niche players.

    To find out more of the report or request some customization :
    Link to the Inquiry before purchase: https://www.marketintelreports.com/inquiry-before-buying.php?id=ihr0007

    Table of Contents

    1 Industry Outlook
    1.1 Industry Overview
    1.2 Industry Trends
    1.3 PEST Analysis
    2 Report Outline
    2.1 Report Scope
    2.2 Report Summary
    2.3 Research Methodology
    2.4 Report Assumptions
    3 Market Snapshot
    3.1 Total Addressable Market
    3.2 Segmented Addressable Market
    3.3 Related Markets
    3.3.1 Interventional Cardiology
    3.3.2 Stents
    3.3.3 Angioplasty
    4 Market Outlook
    4.1 Market Definition – Infoholic Research
    4.2 Importance of Aortic Aneurysm Repair Devices
    4.3 Complications of Aortic Aneurysm
    4.4 Risk Factors for Aortic Aneurysm
    4.5 Types of Aneurysm
    4.6 Market Segmentation
    4.7 Porter 5(Five) Forces
    5 Market Characteristics
    5.1 Evolution
    5.2 Symptoms of Aortic Aneurysm
    5.3 Market Dynamics
    5.3.1 Drivers
    5.3.1.1 Rising geriatric population
    5.3.1.2 High prevalence of tobacco smoking
    5.3.1.3 Growing acceptance for minimally invasive endovascular surgeries
    5.3.1.4 Favorable reimbursement conditions
    5.3.2 Opportunities
    5.3.2.1 Market expansion opportunities in emerging nations
    5.3.2.2 Mergers & acquisitions
    5.3.2.3 Increasing clinical trials
    5.3.3 Restraints
    5.3.3.1 Stringent regulations for approval
    5.3.3.2 Risk associated with the procedure
    5.3.3.3 Lack of awareness
    5.4 DRO – Impact Analysis
    5.5 Key Stakeholders
    6 Types: Market Size and Analysis
    6.1 Overview
    6.2 Abdominal Aortic Aneurysm
    6.2.1 Procedure Type
    6.2.1.1 Open surgery
    6.2.1.2 Abdominal endovascular aneurysm repair
    6.2.2 Location Types
    6.3 Thoracic Aortic Aneurysm
    6.3.1 Procedure Type
    6.3.1.1 Open surgery
    6.3.1.2 Thoracic endovascular aortic aneurysm
    6.3.2 Location Types
    7 Products: Market Size and Analysis
    7.1 Overview
    7.2 Stent Grafts
    7.3 Catheters
    7.4 Others
    Continued....................


    Complete Report Details @ https://www.marketintelreports.com/report/ihr0007/worldwide-aortic-aneurysm-market-trends-and-drivers-restraints-and-opportunities-20172023

    About us:
    MIR intends to be a one-stop shop with an intuitive design, exhaustive database, expert assistance, secure cart checkout and data privacy integrated. It curates the list of reports, publishers and studies to ensure that the database is constantly updated to dynamically meet the targeted, specific needs of our clients.
    MarketIntelReports currently has more than 2.5 million titles and 200 publishers on our platform and are growing consistently to fill the “World Intelligence Demand – Supply Gap”. We cover more than 15 industry verticals being: Automotive, Electronics, Manufacturing, Pharmaceuticals, Healthcare, Chemicals, Building & Construction, Agriculture, Food & Beverages, Banking & Finance, Media and Government, Public Sector Studies.


    Lakshmi
    1-302-261-5343
    sales@marketintelreports.com

    Source: EmailWire.Com

    0 0

    (EMAILWIRE.COM, May 05, 2018 ) Singapore -- Market Report on Global Sleep Apnea Device Market:

    Sleep apnea is a condition in which a person stops breathing for few seconds at night either due to airway blockage or because signal from the brain is not received. In severe conditions, a person stops breathing for more than 10 times in an hour.

    The American Journal of Epidemiology stated that in 2013, around 26% of the adults aged 30–70 years had some form of sleep apnea, whereby 16% of them had mild sleep apnea and 10% had severe sleep apnea.The Global Sleep Apnea Device Market is estimated to witness a CAGR of 7.6% during the forecast period 2017–2023.

    To access the full table of contents of the report click below:
    Link to the table of contents: https://www.marketintelreports.com/report/ihr0009/worldwide-sleep-apnea-device-market-trends-and-drivers-restraints-and-opportunities-20172023

    Among the various forms of sleep apnea, obstructive sleep apnea (OSA) is the most common type. According to the WHO around 100 million people worldwide have OSA. In the US, OSA is said to affect 1 in 4 men and 1 in 9 women, which totals to 23 million working adults. Center for Disease Control and Prevention has also found that the annual healthcare cost for OSA in the US is $165 billion, which is higher than asthma and obesity. Sleep apnea is resulting in reduced productivity at work and increase in road accidents. The National Highway Traffic Safety Administration has estimated that around 100,000 car accidents, 40,000 injuries, and 1,550 deaths per year are caused due to driver’s fatigue.

    The Global Sleep Apnea Devices Market is growing due to factors such as the rising usage of oral appliances, growing awareness of ill effects of untreated sleep apnea in developed countries, technological advances in diagnostics and therapeutic devices, and the increasing number of lifestyle diseases such as diabetes and obesity. However, alternative treatment for sleep apnea, lack of patient compliance, and stringent regulatory approval are some of the factors hampering the market. The market in India, Brazil, and China are also expected to grow at an accelerated pace during the forecast period.

    Scope:

    The report provides complete details about the usage and adoption rate of sleep apnea devices in various verticals and regions. Thus, the key stakeholders can know about the major trends, drivers, investments, and vertical player’s initiatives. Moreover, the report provides details about the major challenges that impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in specific verticals to analyze before investing or expanding the business in this market
    .
    To find out more of the report or request some customization:
    Link to the Inquiry before purchase: https://www.marketintelreports.com/inquiry-before-buying.php?id=ihr0009

    Key players

    The market leaders for sleep apnea devices are ResMed, Philips Healthcare, Becton Dickinson and Company (CareFusion), and Fisher and Paykel. Other leading players in the market include SomnoMed, Compumedics, Cadwell Laboratories, Imthera Medical, Itamar Medical, and BMC Medical.

    Table of contents

    1 Industry Outlook
    1.1 Industry Overview
    1.2 Industry Trends
    1.3 PEST Analysis
    2 Report Outline
    2.1 Report Scope
    2.2 Report Summary
    2.3 Research Methodology
    2.4 Report Assumptions
    3 Market Snapshot
    3.1 Total Addressable Market (TAM)
    3.2 Segmented Addressable Market (SAM)
    3.3 Related Markets
    3.3.1 Chronic Obstructive Pulmonary Disease
    3.3.2 Anesthesia
    3.3.3 Pulmonary Medicine
    4 Market Outlook
    4.1 Market Definition – Infoholic Research
    4.2 Evolution
    4.3 Types of Sleep Apnea
    4.4 Symptoms of Sleep Apnea
    4.5 Technologically Advanced Products
    4.6 Market Segmentation
    4.7 Porter 5(Five) Forces
    5 Market Characteristics
    5.1 Effects of Untreated Sleep Apnea
    5.2 Market Dynamics
    5.2.1 Drivers
    5.2.1.1 Rising usage of oral appliances
    5.2.1.2 Growing awareness of ill effects of untreated sleep apnea in developed countries
    5.2.1.3 Technological advances in diagnostics and therapeutic devices
    5.2.2 Opportunities
    5.2.2.1 Huge pool of undiagnosed sleep apnea patients
    5.2.2.2 Emerging markets in developing countries
    5.2.3 Restraints
    5.2.3.1 Stringent regulations for approval
    5.2.3.2 Alternative treatment for sleep apnea
    5.3 DRO – Impact Analysis
    5.4 Key Stakeholders
    6 Product: Market Size and Analysis
    6.1 Overview
    6.2 Diagnostics Devices
    6.2.1 Home Sleep Testing
    6.2.2 CPAP Titration
    6.2.3 Polysomnography (PSG) Devices
    6.3 Therapeutic Devices
    6.3.1 Oral Appliances
    6.3.2 Positive Airway Pressure (PAP) Machines
    6.3.3 PAP Consumables
    7 End-users: Market Size and Analysis
    7.1 Overview
    7.2 Hospitals and Sleep Laboratories
    7.3 Home Care

    Continued..........................

    Complete Report with Details @ https://www.marketintelreports.com/report/ihr0009/worldwide-sleep-apnea-device-market-trends-and-drivers-restraints-and-opportunities-20172023

    About us:

    MIR intends to be a one-stop shop with an intuitive design, exhaustive database, expert assistance, secure cart checkout and data privacy integrated. It curates the list of reports, publishers and studies to ensure that the database is constantly updated to dynamically meet the targeted, specific needs of our clients.
    MarketIntelReports currently has more than 2.5 million titles and 200 publishers on our platform and are growing consistently to fill the “World Intelligence Demand – Supply Gap”. We cover more than 15 industry verticals being: Automotive, Electronics, Manufacturing, Pharmaceuticals, Healthcare, Chemicals, Building & Construction, Agriculture, Food & Beverages, Banking & Finance, Media and Government, Public Sector Studies.


    Lakshmi
    1-302-261-5343
    sales@marketintelreports.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, May 05, 2018 ) Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Head And Neck Cancer-Pipeline Review, H1 2018, provides an overview of the Head And Neck Cancer (Oncology) pipeline landscape.

    Head and Neck Cancer is a cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx). The common symptoms of cancer of the head and neck include persistent pain in the throat, pain or difficulty with swallowing, persistent hoarseness or a change in voice, pain in the ear and bleeding in the mouth or throat. The disease may be controlled by chemotherapy and radiation therapy.

    Complete Report is Available@ http://www.reportsweb.com/inquiry&RW00011940882/sample

    Report Highlights
    Publisher's Pharmaceutical and Healthcare latest pipeline guide Head And Neck Cancer-Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Head And Neck Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Head And Neck Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Head And Neck Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 21, 113, 120, 6, 75, 20 and 9 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 10, 8, 15, 4 and 1 molecules, respectively.

    Head And Neck Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Buy Report@ http://www.reportsweb.com/buy&RW00011940882/buy/2500

    Key Players:
    3SBio Inc, 4SC AG, AbbVie Inc, Abion Inc, Adaptimmune Therapeutics Plc, Admedus Ltd, Aduro BioTech Inc, Advaxis Inc, Advenchen Laboratories LLC, Affimed GmbH, Altor BioScience Corp, Ambrx Inc, amcure GmbH, Amgen Inc, arGEN-X BV, ArQule Inc, Array BioPharma Inc, Ascentage Pharma Group Corp Ltd, Aspyrian Therapeutics Inc, Astellas Pharma Inc, Astex Pharmaceuticals Inc, AstraZeneca Plc, Atara Biotherapeutics Inc, Aurigene Discovery Technologies Ltd, AVEO Pharmaceuticals Inc, Bayer AG, BeiGene Ltd, Benitec Biopharma Ltd, Bexion Pharmaceuticals LLC, Bicycle Therapeutics Ltd, BioDiem Ltd, Biohaven Pharmaceutical Holding Company Ltd, Biomics Biotechnologies Co Ltd, Bionovis SA, BioNTech AG, Biothera Pharmaceutical Inc, Boehringer Ingelheim GmbH, Boston Biomedical Inc, Bristol-Myers Squibb Co, CBT Pharmaceuticals Inc, CEL-SCI Corp, Celgene Corp, Cell Medica Ltd, Celldex Therapeutics Inc, Cellectar Biosciences Inc, Celprogen Inc, Checkpoint Therapeutics Inc, Corvus Pharmaceuticals Inc, Cotinga Pharmaceuticals Inc, Cristal Therapeutics BV, Curevac AG, Cyclacel Pharmaceuticals Inc, CytImmune Sciences Inc, CytomX Therapeutics Inc, Daiichi Sankyo Co Ltd, Denceptor Therapeutics Ltd, DNJ Pharma Inc, Dynavax Technologies Corp, Eisai Co Ltd, Eli Lilly and Co, Enzene Biosciences Ltd, Etubics Corp, Eureka Therapeutics Inc, Exelixis Inc, F. Hoffmann-La Roche Ltd, Fate Therapeutics Inc, Formation Biologics Inc, Forty Seven Inc, Fujifilm Holdings Corporation, G&E Herbal Biotechnology Co Ltd, Galectin Therapeutics Inc, Genelux Corp, Genentech Inc, GeneSegues Inc, Genmab A/S, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd, Gliknik Inc, Glycotope GmbH, Hanmi Pharmaceuticals Co Ltd, Harbin Gloria Pharmaceuticals Co Ltd, Hookipa Biotech AG, Horizon Pharma Plc, Hutchison MediPharma Ltd, Idera Pharmaceuticals Inc, Ignyta Inc, Immatics Biotechnologies GmbH, Immunocore Ltd, Immunomedics Inc, Immunovaccine Inc, Immunovative Therapies Ltd, Immutep Ltd, Incyte Corp, Infinity Pharmaceuticals Inc, Innate Pharma SA, Inovio Pharmaceuticals Inc, InteRNA Technologies BV, Iovance Biotherapeutics Inc, IRX Therapeutics Inc, ISA Pharmaceuticals BV, ISU ABXIS Co Ltd, Jiangsu Hengrui Medicine Co Ltd, Jiangsu Kanion Pharmaceutical Co Ltd, Johnson & Johnson, Jounce Therapeutics Inc, Juno Therapeutics Inc, Kite Pharma Inc, Kura Oncology Inc, Laboratoires Pierre Fabre SA, LATITUDE Pharmaceuticals Inc, Loxo Oncology Inc, Lycera Corp, Lytix Biopharma AS, Mabion SA, MacroGenics Inc, Madrigal Pharmaceuticals Inc., Marsala Biotech Inc, Mateon Therapeutics Inc, MaxiVAX SA, MedImmune LLC, Merck & Co Inc, Merck KGaA, Merrimack Pharmaceuticals Inc, Mersana Therapeutics Inc, Millennium Pharmaceuticals Inc, Mirati Therapeutics Inc, Moderna Therapeutics Inc, Molecular Partners AG, Molecular Templates Inc, Moleculin Biotech Inc, NanoCarrier Co Ltd, NantKwest Inc, Natco Pharma Ltd, NeoImmuneTech Inc, Neonc Technologies Inc, Neumedicines Inc, Novartis AG, Noxopharm Ltd, Oncobiologics Inc, Oncolys BioPharma Inc, Onconova Therapeutics Inc, Oncovir Inc, Ono Pharmaceutical Co Ltd, Otsuka Holdings Co Ltd, Oxford Vacmedix UK Ltd, PDS Biotechnology Corp, Pfizer Inc, Pharma Mar SA, Phosplatin Therapeutics LLC, Plexxikon Inc, PNP Therapeutics Inc, Profectus BioSciences Inc, Provectus Biopharmaceuticals Inc, PsiOxus Therapeutics Ltd, R Pharm, Regeneron Pharmaceuticals Inc, Reliance Life Sciences Pvt Ltd, Sareum Holdings Plc, Selecta Biosciences Inc, Shanghai Henlius Biotech Co Ltd, Shionogi & Co Ltd, Sierra Oncology Inc, Sillajen Biotherapeutics, Sinil Pharmaceutical Co Ltd, Soricimed Biopharma Inc, Sorrento Therapeutics Inc, Sound Pharmaceuticals Inc, Spherium Biomed SL, Sumitomo Dainippon Pharma Co Ltd, SuviCa Inc, SynCore Biotechnology Co Ltd, Systimmune Inc, Takis Srl, Tessa Therapeutics Pte Ltd, Theralase Technologies Inc, Theravectys SA, Tolero Pharmaceuticals Inc, Tosk Inc, Transgene SA, UbiVac LLC, Vaccibody AS, VasGene Therapeutics Inc, Vault Pharma Inc, Vaxeal Holding SA, Vectorite Biomedical Inc, Viracta Therapeutics Inc, Vyriad Inc

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope
    -The pipeline guide provides a snapshot of the global therapeutic landscape of Head And Neck Cancer (Oncology).
    -The pipeline guide reviews pipeline therapeutics for Head And Neck Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    -The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    -The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    -The pipeline guide reviews key companies involved in Head And Neck Cancer (Oncology) therapeutics and enlists all their major and minor projects.
    -The pipeline guide evaluates Head And Neck Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    -The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    -The pipeline guide reviews latest news related to pipeline therapeutics for Head And Neck Cancer (Oncology)

    Inquiry for Report@ http://www.reportsweb.com/inquiry&RW00011940882/buying

    Reasons to buy
    -Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    -Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    -Find and recognize significant and varied types of therapeutics under development for Head And Neck Cancer (Oncology).
    -Classify potential new clients or partners in the target demographic.
    -Develop tactical initiatives by understanding the focus areas of leading companies.
    -Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    -Formulate corrective measures for pipeline projects by understanding Head And Neck Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
    -Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    -Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


    Rajat Sahni
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, May 05, 2018 ) Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Gastric Cancer-Pipeline Review, H1 2018, provides an overview of the Gastric Cancer (Oncology) pipeline landscape.

    Gastric cancer, also called stomach cancer, is a malignant tumor arising from the lining of the stomach. Signs and symptoms of gastric cancer include fatigue, stomach pain, vomiting, weight loss that is unintentional, feeling bloated after eating, heartburn and indigestion. Risk factors include smoking, pernicious anemia, stomach polyps, infection with helicobacter pylori and family history of stomach cancer. Treatment includes surgery, chemotherapy and radiation therapy.

    Complete Report is Available@ http://www.reportsweb.com/inquiry&RW00011940883/sample

    Report Highlights
    Publisher's Pharmaceutical and Healthcare latest pipeline guide Gastric Cancer-Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Gastric Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Gastric Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastric Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 2, 14, 80, 99, 11, 97, 17 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 9, 3, 1, 9 and 2 molecules, respectively.

    Gastric Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Inquiry for Report@ http://www.reportsweb.com/inquiry&RW00011940883/buying

    Key Players:

    3SBio Inc, 4SC AG, AbbVie Inc, Abion Inc, Adaptimmune Therapeutics Plc, Admedus Ltd, Aduro BioTech Inc, Advaxis Inc, Advenchen Laboratories LLC, Affimed GmbH, Altor BioScience Corp, Ambrx Inc, amcure GmbH, Amgen Inc, arGEN-X BV, ArQule Inc, Array BioPharma Inc, Ascentage Pharma Group Corp Ltd, Aspyrian Therapeutics Inc, Astellas Pharma Inc, Astex Pharmaceuticals Inc, AstraZeneca Plc, Atara Biotherapeutics Inc, Aurigene Discovery Technologies Ltd, AVEO Pharmaceuticals Inc, Bayer AG, BeiGene Ltd, Benitec Biopharma Ltd, Bexion Pharmaceuticals LLC, Bicycle Therapeutics Ltd, BioDiem Ltd, Biohaven Pharmaceutical Holding Company Ltd, Biomics Biotechnologies Co Ltd, Bionovis SA, BioNTech AG, Biothera Pharmaceutical Inc, Boehringer Ingelheim GmbH, Boston Biomedical Inc, Bristol-Myers Squibb Co, CBT Pharmaceuticals Inc, CEL-SCI Corp, Celgene Corp, Cell Medica Ltd, Celldex Therapeutics Inc, Cellectar Biosciences Inc, Celprogen Inc, Checkpoint Therapeutics Inc, Corvus Pharmaceuticals Inc, Cotinga Pharmaceuticals Inc, Cristal Therapeutics BV, Curevac AG, Cyclacel Pharmaceuticals Inc, CytImmune Sciences Inc, CytomX Therapeutics Inc, Daiichi Sankyo Co Ltd, Denceptor Therapeutics Ltd, DNJ Pharma Inc, Dynavax Technologies Corp, Eisai Co Ltd, Eli Lilly and Co, Enzene Biosciences Ltd, Etubics Corp, Eureka Therapeutics Inc, Exelixis Inc, F. Hoffmann-La Roche Ltd, Fate Therapeutics Inc, Formation Biologics Inc, Forty Seven Inc, Fujifilm Holdings Corporation, G&E Herbal Biotechnology Co Ltd, Galectin Therapeutics Inc, Genelux Corp, Genentech Inc, GeneSegues Inc, Genmab A/S, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd, Gliknik Inc, Glycotope GmbH, Hanmi Pharmaceuticals Co Ltd, Harbin Gloria Pharmaceuticals Co Ltd, Hookipa Biotech AG, Horizon Pharma Plc, Hutchison MediPharma Ltd, Idera Pharmaceuticals Inc, Ignyta Inc, Immatics Biotechnologies GmbH, Immunocore Ltd, Immunomedics Inc, Immunovaccine Inc, Immunovative Therapies Ltd, Immutep Ltd, Incyte Corp, Infinity Pharmaceuticals Inc, Innate Pharma SA, Inovio Pharmaceuticals Inc, InteRNA Technologies BV, Iovance Biotherapeutics Inc, IRX Therapeutics Inc, ISA Pharmaceuticals BV, ISU ABXIS Co Ltd, Jiangsu Hengrui Medicine Co Ltd, Jiangsu Kanion Pharmaceutical Co Ltd, Johnson & Johnson, Jounce Therapeutics Inc, Juno Therapeutics Inc, Kite Pharma Inc, Kura Oncology Inc, Laboratoires Pierre Fabre SA, LATITUDE Pharmaceuticals Inc, Loxo Oncology Inc, Lycera Corp, Lytix Biopharma AS, Mabion SA, MacroGenics Inc, Madrigal Pharmaceuticals Inc., Marsala Biotech Inc, Mateon Therapeutics Inc, MaxiVAX SA, MedImmune LLC, Merck & Co Inc, Merck KGaA, Merrimack Pharmaceuticals Inc, Mersana Therapeutics Inc, Millennium Pharmaceuticals Inc, Mirati Therapeutics Inc, Moderna Therapeutics Inc, Molecular Partners AG, Molecular Templates Inc, Moleculin Biotech Inc, NanoCarrier Co Ltd, NantKwest Inc, Natco Pharma Ltd, NeoImmuneTech Inc, Neonc Technologies Inc, Neumedicines Inc, Novartis AG, Noxopharm Ltd, Oncobiologics Inc, Oncolys BioPharma Inc, Onconova Therapeutics Inc, Oncovir Inc, Ono Pharmaceutical Co Ltd, Otsuka Holdings Co Ltd, Oxford Vacmedix UK Ltd, PDS Biotechnology Corp, Pfizer Inc, Pharma Mar SA, Phosplatin Therapeutics LLC, Plexxikon Inc, PNP Therapeutics Inc, Profectus BioSciences Inc, Provectus Biopharmaceuticals Inc, PsiOxus Therapeutics Ltd, R Pharm, Regeneron Pharmaceuticals Inc, Reliance Life Sciences Pvt Ltd, Sareum Holdings Plc, Selecta Biosciences Inc, Shanghai Henlius Biotech Co Ltd, Shionogi & Co Ltd, Sierra Oncology Inc, Sillajen Biotherapeutics, Sinil Pharmaceutical Co Ltd, Soricimed Biopharma Inc, Sorrento Therapeutics Inc, Sound Pharmaceuticals Inc, Spherium Biomed SL, Sumitomo Dainippon Pharma Co Ltd, SuviCa Inc, SynCore Biotechnology Co Ltd, Systimmune Inc, Takis Srl, Tessa Therapeutics Pte Ltd, Theralase Technologies Inc, Theravectys SA, Tolero Pharmaceuticals Inc, Tosk Inc, Transgene SA, UbiVac LLC, Vaccibody AS, VasGene Therapeutics Inc, Vault Pharma Inc, Vaxeal Holding SA, Vectorite Biomedical Inc, Viracta Therapeutics Inc, Vyriad Inc

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope
    -The pipeline guide provides a snapshot of the global therapeutic landscape of Gastric Cancer (Oncology).
    -The pipeline guide reviews pipeline therapeutics for Gastric Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    -The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    -The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    -The pipeline guide reviews key companies involved in Gastric Cancer (Oncology) therapeutics and enlists all their major and minor projects.
    -The pipeline guide evaluates Gastric Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    -The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    -The pipeline guide reviews latest news related to pipeline therapeutics for Gastric Cancer (Oncology)

    Buy Report@ http://www.reportsweb.com/buy&RW00011940883/buy/2500

    Reasons to buy
    -Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    -Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    -Find and recognize significant and varied types of therapeutics under development for Gastric Cancer (Oncology).
    -Classify potential new clients or partners in the target demographic.
    -Develop tactical initiatives by understanding the focus areas of leading companies.
    -Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    -Formulate corrective measures for pipeline projects by understanding Gastric Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
    -Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    -Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


    Rajat Sahni
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, May 05, 2018 ) Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Asthma-Pipeline Review, H1 2018, provides an overview of the Asthma (Respiratory) pipeline landscape.

    Asthma is a chronic disease involving the airways in the lungs. These airways, or bronchial tubes, allow air to come in and out of the lungs. Symptoms include shortness of breath, chest tightness or pain, chronic coughing and trouble sleeping due to coughing or wheezing. The predisposing factors include family history, overweight, smoking, exposure to exhaust fumes or other types of pollution and exposure to occupational triggers, such as chemicals used in farming, hairdressing and manufacturing. Treatment includes inhaled corticosteroids, leukotriene modifiers, antihistamines and decongestants.

    Complete Report is Available@ http://www.reportsweb.com/inquiry&RW00011940895/sample

    Report Highlights
    Publisher's Pharmaceutical and Healthcare latest pipeline guide Asthma-Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Asthma (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Asthma (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Asthma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 18, 40, 27, 1, 112, 26 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 29 and 8 molecules, respectively.

    Asthma (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Inquiry for Report@ http://www.reportsweb.com/inquiry&RW00011940895/buying

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope
    -The pipeline guide provides a snapshot of the global therapeutic landscape of Asthma (Respiratory).
    -The pipeline guide reviews pipeline therapeutics for Asthma (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    -The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    -The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    -The pipeline guide reviews key companies involved in Asthma (Respiratory) therapeutics and enlists all their major and minor projects.
    -The pipeline guide evaluates Asthma (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    -The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    -The pipeline guide reviews latest news related to pipeline therapeutics for Asthma (Respiratory)

    Reasons to buy
    -Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    -Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    -Find and recognize significant and varied types of therapeutics under development for Asthma (Respiratory).
    -Classify potential new clients or partners in the target demographic.
    -Develop tactical initiatives by understanding the focus areas of leading companies.
    -Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    -Formulate corrective measures for pipeline projects by understanding Asthma (Respiratory) pipeline depth and focus of Indication therapeutics.
    -Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    -Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

    Buy Report@ http://www.reportsweb.com/buy&RW00011940895/buy/2500


    Rajat Sahni
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, May 05, 2018 ) Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Heavy Metal Poisoning-Pipeline Review, H1 2018, provides an overview of the Heavy Metal Poisoning (Toxicology) pipeline landscape.

    Heavy metal poisoning is the accumulation of heavy metals, in toxic amounts, in the soft tissues of the body. Sources of toxicity can include environmental, water supply, industrial and hobbies. Symptoms include headaches, drowsiness, confusion, seizures, nausea, vomiting, abdominal cramps, tinnitus, goiter, anorexia and diarrhea. Treatment includes chelation therapy.

    Complete Report is Available@ http://www.reportsweb.com/inquiry&RW00011940902/sample

    Report Highlights
    Publisher's Pharmaceutical and Healthcare latest pipeline guide Heavy Metal Poisoning-Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Heavy Metal Poisoning (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Heavy Metal Poisoning (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Heavy Metal Poisoning and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 2 and 4 respectively. Similarly, the Universities portfolio in IND/CTA Filed, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively.

    Heavy Metal Poisoning (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Buy Report@ http://www.reportsweb.com/buy&RW00011940902/buy/2000

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope
    -The pipeline guide provides a snapshot of the global therapeutic landscape of Heavy Metal Poisoning (Toxicology).
    -The pipeline guide reviews pipeline therapeutics for Heavy Metal Poisoning (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    -The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    -The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    -The pipeline guide reviews key companies involved in Heavy Metal Poisoning (Toxicology) therapeutics and enlists all their major and minor projects.
    -The pipeline guide evaluates Heavy Metal Poisoning (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    -The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    -The pipeline guide reviews latest news related to pipeline therapeutics for Heavy Metal Poisoning (Toxicology)

    Reasons to buy
    -Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    -Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    -Find and recognize significant and varied types of therapeutics under development for Heavy Metal Poisoning (Toxicology).
    -Classify potential new clients or partners in the target demographic.
    -Develop tactical initiatives by understanding the focus areas of leading companies.
    -Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    -Formulate corrective measures for pipeline projects by understanding Heavy Metal Poisoning (Toxicology) pipeline depth and focus of Indication therapeutics.
    -Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    -Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

    Discount Inquiry@ http://www.reportsweb.com/inquiry&RW00011940902/discount


    Rajat Sahni
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, May 05, 2018 ) Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Radiation Injury-Pipeline Review, H1 2018, provides an overview of the Radiation Injury (Toxicology) pipeline landscape.

    Radiation injury is damage to tissues caused by exposure to ionizing radiation. Symptoms depend on whether radiation exposure involves the whole body or is limited to a small portion of the body. At high doses, whole-body exposure causes acute radiation illness, and partial-body exposure causes local radiation injury.

    Complete Report is Available@ http://www.reportsweb.com/inquiry&RW00011940903/sample

    Report Highlights
    Publisher's Pharmaceutical and Healthcare latest pipeline guide Radiation Injury-Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Radiation Injury (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Radiation Injury (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Radiation Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 7, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

    Radiation Injury (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Buy Report@ http://www.reportsweb.com/buy&RW00011940903/buy/2000

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope
    -The pipeline guide provides a snapshot of the global therapeutic landscape of Radiation Injury (Toxicology).
    -The pipeline guide reviews pipeline therapeutics for Radiation Injury (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    -The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    -The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    -The pipeline guide reviews key companies involved in Radiation Injury (Toxicology) therapeutics and enlists all their major and minor projects.
    -The pipeline guide evaluates Radiation Injury (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    -The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    -The pipeline guide reviews latest news related to pipeline therapeutics for Radiation Injury (Toxicology)

    Reasons to buy
    -Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    -Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    -Find and recognize significant and varied types of therapeutics under development for Radiation Injury (Toxicology).
    -Classify potential new clients or partners in the target demographic.
    -Develop tactical initiatives by understanding the focus areas of leading companies.
    -Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    -Formulate corrective measures for pipeline projects by understanding Radiation Injury (Toxicology) pipeline depth and focus of Indication therapeutics.
    -Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    -Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

    Discount Inquiry@ http://www.reportsweb.com/inquiry&RW00011940903/discount


    Rajat Sahni
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, May 05, 2018 ) Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Kidney Disease (Chronic Renal Failure)-Pipeline Review, H1 2018, provides an overview of the Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) pipeline landscape.

    Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups and swelling of feet and ankles. The predisposing factors include age, diabetes, high blood pressure, heart disease, smoking, obesity and high cholesterol.

    Complete Report is Available@ http://www.reportsweb.com/inquiry&RW00011940891/sample

    Key Players:
    Allena Pharmaceuticals Inc
    Angion Biomedica Corp
    apceth Biopharma GmbH
    Astellas Pharma Inc
    AstraZeneca Plc
    Bayer AG
    Boehringer Ingelheim GmbH
    Boryung Pharmaceutical Co Ltd
    Cellmid Ltd
    Chugai Pharmaceutical Co Ltd
    Corvidia Therapeutics
    CTI BioPharma Corp
    DURECT Corp
    Evotec AG
    Gilead Sciences Inc
    GNI Group Ltd
    Lupin Ltd
    Navya Biologicals Pvt Ltd
    Novartis AG
    OPKO Health Inc
    Otsuka Holdings Co Ltd
    Prolong Pharmaceuticals LLC
    ProMetic Life Sciences Inc
    Reata Pharmaceuticals Inc
    Relypsa Inc
    Resverlogix Corp
    Rockwell Medical Inc
    Sanwa Kagaku Kenkyusho Co Ltd
    Sarfez Pharmaceuticals Inc
    Taisho Pharmaceutical Holdings Co Ltd
    Toray Industries Inc
    Tricida Inc
    Unity Biotechnology Inc
    Vascular BioSciences
    VESSL Therapeutics Ltd
    Vicore Pharma AB

    Report Highlights
    Publisher's Pharmaceutical and Healthcare latest pipeline guide Chronic Kidney Disease (Chronic Renal Failure)-Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 4, 8, 16, 1, 22 and 4 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

    Buy Report@ http://www.reportsweb.com/buy&RW00011940891/buy/2000

    Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope
    -The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones).
    -The pipeline guide reviews pipeline therapeutics for Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    -The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    -The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    -The pipeline guide reviews key companies involved in Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
    -The pipeline guide evaluates Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    -The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    -The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones)

    Reasons to buy
    -Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    -Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    -Find and recognize significant and varied types of therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones).
    -Classify potential new clients or partners in the target demographic.
    -Develop tactical initiatives by understanding the focus areas of leading companies.
    -Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    -Formulate corrective measures for pipeline projects by understanding Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
    -Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    -Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

    Discount Inquiry@ http://www.reportsweb.com/inquiry&RW00011940891/discount


    Rajat Sahni
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, May 05, 2018 ) Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Kidney Transplant Rejection-Pipeline Review, H1 2018, provides an overview of the Kidney Transplant Rejection (Immunology) pipeline landscape.

    Kidney transplantation is a therapy performed to replace a diseased kidney with a healthy kidney from another person. Risk factors associated with transplantation are bleeding, infection, blockage of the blood vessels to the new kidney, leakage of urine or blockage of urine in the ureter and initial lack of function of the new kidney. Treatment includes immunosuppressive drugs to prevent organ rejection.

    Complete Report is Available@ http://www.reportsweb.com/inquiry&RW00011912491/sample

    Report Highlights
    Publisher's Pharmaceutical and Healthcare latest pipeline guide Kidney Transplant Rejection-Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Kidney Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

    The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Kidney Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Kidney Transplant Rejection and features dormant and discontinued projects.

    The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 7, 10, 10, 16 and 3 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively.

    Kidney Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

    The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Buy Report@ http://www.reportsweb.com/buy&RW00011912491/buy/2000

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope
    -The pipeline guide provides a snapshot of the global therapeutic landscape of Kidney Transplant Rejection (Immunology).
    -The pipeline guide reviews pipeline therapeutics for Kidney Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    -The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    -The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    -The pipeline guide reviews key companies involved in Kidney Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects.
    -The pipeline guide evaluates Kidney Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    -The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    -The pipeline guide reviews latest news related to pipeline therapeutics for Kidney Transplant Rejection (Immunology)

    Reasons to buy
    -Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    -Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    -Find and recognize significant and varied types of therapeutics under development for Kidney Transplant Rejection (Immunology).
    -Classify potential new clients or partners in the target demographic.
    -Develop tactical initiatives by understanding the focus areas of leading companies.
    -Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    -Formulate corrective measures for pipeline projects by understanding Kidney Transplant Rejection (Immunology) pipeline depth and focus of Indication therapeutics.
    -Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    -Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

    Discount Inquiry@ http://www.reportsweb.com/inquiry&RW00011912491/discount


    Rajat Sahni
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, May 05, 2018 ) Global Healthcare Providers industry profile provides top-line qualitative and quantitative summary information including: Sector size (value 2013-17, and forecast to 2022). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the Sector.

    Synopsis
    Essential resource for top-line data and analysis covering the global healthcare providers Sector. Includes Sector size and segmentation data, textual and graphical analysis of Sector growth trends and leading companies.

    Complete Report is Available@ http://www.reportsweb.com/inquiry&RW00011940781/sample

    Key Highlights
    -The healthcare providers sector is valued as total expenditure on healthcare in each country. This includes final consumption spending on healthcare goods and services.
    -Goods and services in this sector include inpatient, outpatient, long-term medical care, medical goods including pharmaceuticals and supplies, and collective services and capital formation such as administration requirements and development costs.
    -Public spending (e.g. by national and local governments and social security schemes) and private spending (e.g. payments made by private-sector health insurers and individual out-of-pocket expenditures) are both included.
    -Note that with regards to distribution data (whereby data is broken down to private or government expenditure), the government expenditure segment also includes healthcare insurance funded by private insurers where such insurance is mandatory, for example in the United States. Any other non-mandatory privately-funded insurance comes under the "private" segment.
    -Any currency conversions used in the creation of this report have been calculated using constant 2017 annual average exchange rates.
    -The global healthcare providers sector had total revenues of $8,000.8bn in 2017, representing a compound annual growth rate (CAGR) of 5.7% between 2013 and 2017.
    -The outpatient care segment was the sector's most lucrative in 2017, with total revenues of $3,186.9bn, equivalent to 39.8% of the sector's overall value.
    -The growth of the global healthcare providers sector in recent years has been driven by the emergence of sectors within the Asian-Pacific region. Growing population and rising income in these countries, along with governments' attempts to achieve universal health coverage, have boosted public expenditure. Developed countries as seen mainly in Japan, Europe and Canada, face increasing costs of public healthcare provision that stem from ageing population.

    Buy Report@ http://www.reportsweb.com/buy&RW00011940781/buy/1495

    Scope
    -Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the global healthcare providers Sector
    -Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the global healthcare providers Sector
    -Leading company profiles reveal details of key healthcare providers Sector players' global operations and financial performance
    -Add weight to presentations and pitches by understanding the future growth prospects of the global healthcare providers Sector with five year forecasts

    Reasons to buy
    -What was the size of the global healthcare providers Sector by value in 2017-
    -What will be the size of the global healthcare providers Sector in 2022-
    -What factors are affecting the strength of competition in the global healthcare providers Sector-
    -How has the Sector performed over the last five years-
    -What are the main segments that make up the global healthcare providers Sector-

    Discount Inquiry@ http://www.reportsweb.com/inquiry&RW00011940781/discount


    Rajat Sahni
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, May 07, 2018 ) The medical marijuana market is estimated to represent a global market of USD 13.88 billion by 2017 with growth rate of 18.3%. According to the National Institute on Drug Abuse (NIDA), Marijuana (also referred as cannabis) is the dried leaves of female flowers of hemp plant which contain psychoactive properties. Delta- 9- tetrahydrocannabinol (Delta-9-THC) is the important psychoactive ingredient, the most abundant cannabinoid presents in marijuana. The movement to accept cannabis as a medicine is propel by multiple factors, including inadequate relief of current available treatment approaches for number of chronic disease conditions such as Crohn’s disease, multiple Sclerosis, cancer, Alzheimer’s disease, and chronic pain. Such conditions are frequently cited by the proponents of marijuana i.e. cannabis for medical use. The market for medical marijuana is primarily driven by the growing application of marijuana in mentioned medical conditions.

    Furthermore, large number of companies are increasingly investing in this market to capture significant revenue share. For example, Australia based MMJ PhytoTech Limited is considered to be the pioneer in the development of medical cannabis for international market, under regulated medical cannabis laws. The company is the first medical grade cannabis (MGC) company to list on the ASX. PhytoTech is primarily focused on the research and development activities on MGC therapeutics to be used in various medical applications. The company is aimed to become a leader in commercialization of cannabinoids based therapeutic products. Such initiatives would in turn help this market to establish healthy platform, hence drives the market growth. However, low penetration of marijuana for medical application in some developed as well as developing countries hamper the market growth.

    Complete Report is Available@ http://www.reportsweb.com/inquiry&RW00011327825/sample

    The market is categorized as Migraine, Arthritis, Cancer, Chronic Pain, and Others. Chronic pain segment achieved largest share of the total medical marijuana market, captured 35.26% share of the market. The use of pain medication is rapidly increasing, imposing a major burden on the healthcare system. The use of medical marijuana is reported to significantly alleviate pain symptoms. Its application in cancer and arthritis is also considered to be growing in near future due to advancements and increasing awareness among patient population.
    Regionally, developed countries of North America and Europe is the big market for medical marijuana. In Europe, medical cannabis is imported from Holland to the European countries such as Czech Republic, Croatia, Switzerland, Italy, Netherland, and others. Increasing number of prescriptions for the cannabis for various medical indication have surged the demand for medical marijuana in developed regions which will drive the market growth. For example, according to the Marijuana Business Fact Book (2014), more than 730,000 patients have received medical recommendation to use cannabis for different medical indication. Similarly, Health Canada, official forecast projected that medical cannabis patients will grow to 1.2% of the total Canadian population in next 10 years. This industry is predicated to grow at 25% to 28% (i.e. more than 400,000 patients) patient growth by 2024. Huge demand coupled with necessity to include cannabis for medical application will support the market growth.
    Owing to its huge benefits in medical application, the market is predicted to grow at slow but steady growth rate in developing regions. Government of some developing regions are considering marijuana as a potential economic opportunity. For example, Agriculture Minister of the Israeli government is researching to develop best ways to grow cannabis. The Health Ministry, having its own medical cannabis department is planning to extend the various licenses to support cannabis industry in the country. Such types of initiatives would in turn support the market growth to great extent during the forecast period.

    Companies such as Cannabis Sativa, Cara Therapeutics, Lexaria Corp, United Cannabis Corporation, CannaGrow Holdings Inc., International Consolidated Companies, Inc. and others are present in this market. These companies are investing huge amount of their revenue share on research and development activities to develop novel marijuana based therapeutics for medical applications.

    Buy Report@ http://www.reportsweb.com/buy&RW00011327825/buy/3235

    The market size and forecast for each segment has been provided for the period 2014 to 2025, considering 2016 as the base year. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2017 to 2025 for every reported segment.
    The years considered for the study are:
    Historical Year – 2014 & 2015
    Base Year – 2016
    Estimated Year – 2017
    Projected Year – 2025
    TARGET AUDIENCE
    Traders, Distributors, And Suppliers
    Manufacturers
    Hospitals
    Government and Regional Agencies and Research Organizations
    Consultants
    Distributors

    SCOPE OF THE REPORT
    The scope of this report covers the market by its major segments, which include as follows:

    MARKET, BY TYPES
    Migraine
    Arthritis
    Cancer
    Chronic Pain
    Others

    MARKET, BY REGION
    North America
    Europe
    Asia Pacific
    Rest of the World

    MARKET, BY COUNTRY
    Further Breakdown of The North America Market
    U.S.
    Canada
    Further Breakdown of The Europe Market
    Germany
    France
    Finland
    Romania
    Italy
    Rest of Europe
    Further Breakdown of The APAC Market
    India
    China
    Rest of APAC
    Further Breakdown of The Rest of the World Market
    Middle East and Africa
    Latin America

    Discount Inquiry@ http://www.reportsweb.com/inquiry&RW00011327825/discount


    Rajat Sahni
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, May 07, 2018 ) The next generation sequencing market is estimated to represent a global market of USD 5,618 million by 2017 with growth rate of 9.1%. Next-generation sequencing (NGS) involves an advanced level of genetic sequencing which is a level above the conventional methods such as capillary electrophoresis-based Sanger sequencing. NGS procedure is a multi-step process where a number of smaller laboratory processes combine to form the whole next-generation sequencing process. This includes pre-sequencing steps of sample preparation, target enrichment, library preparation under NGS pre-sequencing, the sequencing procedure under NGS Sequencing and data warehousing and data interpretation under NGS data analysis in the workflow outlook.

    NGS technology is used for the wide array of sequencing approaches such as transcriptome, genome, and epigenome of any organism. Sequencing techniques differ primarily based on the development of DNA/RNA samples, i.e. tissue type, organism, experimental conditions, and others. This technology is very effective and flexible for the variety of study in large genomic centers to small-scale laboratories. NGS sequencing method is different from Sanger sequencing at a fundamental level in which instead of one fragment being expanded a time, over millions of fragments are expanded in simultaneous reactions which greatly enhance the sequencing capabilities.

    Complete Report is Available@ http://www.reportsweb.com/inquiry&RW00011433642/sample

    Market Dynamic
    The market is primarily driven by the constant growth in demand for genetic sequencing owing to its cost-effectiveness. According to the National Human Genome Research Institute (NHGRI) , and the significant decrease in the costs for genome sequencing have been witnessed since the first Human Genome Project was initiated in 2000. This has led an increase in uptake of genetic sequencing by various end users such as biotechnology companies, pharmaceutical industries and other, leading to driving the market growth. Furthermore, next-generation sequencing technologies have expanded applications in oncology, infectious disorders, and idiopathic diseases analysis. Additionally, with the technological development of whole-genome sequencing, novel avenues of applicability such as human leukocyte antigen (HLA) and prenatal testing have also been developed, supporting the market growth to great extent.

    Technology Takeaway
    In terms of technological level, next-generation sequencing is categories into Whole Exon Sequencing (WES) , Whole Genome Sequencing (WGS) , Targeted Sequencing and Resequencing Technique. These approaches encompass smaller fragment length sequencing approaches such as de novo sequencing and others. NGS resequencing and de novo sequencing provide laboratories with a capability to produce high throughput sequencing results.

    Targeted sequencing captured the significant share of the global market. This sequencing enables researchers to isolate and the sequence-specific subset of genes of the genome. It allows researchers to focus data analysis and specific area of interest time with higher coverage level. For example, targeted resequencing method can cover more than 500-1000× region of genome compared to the traditional WGS study (achieves coverage levels of 30-50× per genome) . This advantage help researcher to identify rare variations which are impossible with WGS and CE-based sequencing techniques.

    Application Takeaway
    Oncology, Reproductive Health, Clinical Investigation, Consumer Genomics, Immune Monitoring, and others are categorized under application segment. NGS technique has had the greatest applications for clinical research and development of cancer diagnostics and therapeutics. NGS has major applications in oncology wherein it is used to sequence and Catalogue gene mutations for further development of novel cancer diagnostic and therapeutic methodologies. With the expected reduction in the cost of whole-genome sequencing, applications of NGS in oncology will witness the significant increase in demand throughout the forecast period.

    Product & Services Takeaway
    In terms of products & services, the market is divided as Pre-Sequencing Products (i.e. NGS library preparation kits, NGS semi-automated library preparation, NGS automated library preparation, Clonal amplification) , Sequencing Services, and Data Analysis. Pre-Sequencing phase includes the sample preparation processes that are undertaken prior to the sequencing step. The end-user segment is bifurcated as Academic Research, Hospital Settings, Clinical Laboratories, and others.

    Buy Report@ http://www.reportsweb.com/buy&RW00011433642/buy/3235

    North America Next Generation Sequencing Market
    Regional Takeaway
    Regionally, North America and Europe accounted for the largest share of the global market. Rising research and development activities coupled with increasing demand for advanced sequencing techniques support the market growth in these regions. Furthermore, rapid penetration of personalized medicine and companion diagnostics techniques further boost the market growth. On another side, the establishment of organizations such as Beijing Genomics Institute (BGI) supports the overall Asia Pacific market growth. For instance, it has been reported that BGI has installed over 120 HiSeq (Illumina) 2000 genome sequencers in 2010. Owing to this, BGI NGS laboratory in Hong Kong is considered to be among the few very high capacity next-generation genome sequencing facilities.

    Key Vendor Takeaway
    Companies such as Illumina, Inc., Qiagen, Agilent Technologies, Genomatix GmbH, and Roche are profiles in the study. Wide product offering coupled with increasing research and development activities helped companies to achieve significant revenue share. For example, Illumina offers the wide range of NGS instruments, ranging from the benchtop MiniSeq System to the advanced NovaSeq 6000 System. The company presents comprehensive solutions for NGS workflow such as sequencing instrument, library preparation kits, bioinformatics and automated data analysis tools.

    The market size and forecast for each segment has been provided for the period 2014 to 2025, considering 2015 as the base year. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2016 to 2025 for every reported segment.

    The years considered for the study are:
    Historical Year – 2014 & 2015
    Base Year – 2015
    Estimated Year – 2016
    Projected Year – 2025

    TARGET AUDIENCE
    Traders, Distributors, And Suppliers
    Manufacturers
    Hospitals
    Government and Regional Agencies and Research Organizations
    Consultants
    Distributors

    SCOPE OF THE REPORT
    The scope of this report covers the market by its major segments, which include as follows:

    MARKET, BY TECHNOLOGY
    Whole Exon Sequencing (WES)
    Whole Genome Sequencing (WGS)
    Targeted Sequencing
    Resequencing Technique

    MARKET, BY APPLICATION
    Oncology
    Reproductive Health
    Clinical Investigation
    Consumer Genomics
    Immune Monitoring
    Others

    MARKET, BY PRODUCT & SERVICES
    Pre-Sequencing Products
    Sequencing Services
    Data Analysis

    MARKET, BY END USE
    Academic Research
    Hospital Settings
    Clinical Laboratories
    Others

    MARKET, BY REGION
    North America
    Europe
    Asia Pacific
    Rest of the World

    Discount Inquiry@ http://www.reportsweb.com/inquiry&RW00011433642/discount

    MARKET, BY COUNTRY
    Further Breakdown of The North America Market
    U.S.
    Canada
    Further Breakdown of The Europe Market
    Germany
    France
    Rest of Europe
    Further Breakdown of The APAC Market
    India
    China
    Rest of APAC
    Further Breakdown of The Rest of the World Market
    Middle East and Africa
    Latin America


    Rajat Sahni
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, May 07, 2018 ) Point of care testing is a medical tool, designed to perform outside the physical facilities such as clinical laboratories. These tests are primarily used to diagnose various chronic disease conditions such as diabetes, cardiovascular disorders, infectious diseases and others.

    Market Dynamics
    Point of care diagnostics market is primarily driven by the rising demand for home healthcare coupled with continuous aging population across the world. World Health Organization (WHO) has projected that aging population, over 60 years, will be doubled, from 12% (2015) to 22% (2050) . Similarly, According to the Population Reference Bureau (PRB) , geriatric population (over 65 years) is projected to double in America by the next few years. Considering these facts, several initiatives undertaken by governments to shorten hospital stays by establishing out-patient care models which will surge in demand for POC diagnostics, augmenting the market growth.

    Additionally, favorable regulatory initiatives, aimed at promoting a point of care diagnosis is anticipated to serve the industry as a high impact rendering driver. For example, the U.S. government (U.S. FDA) introduced CLIA (clinical laboratory improvement amendments) in partnership with the Centres for Medicare & Medicaid Services (CMS) and the Centre for Disease Control (CDC) . This regulation aims to conduct laboratory inspection and enforce regulatory compliances in order to assure quality laboratory testing, expected to boost usage rates of POC during the forecast period. Furthermore, increasing funding, from organizations such as National Institute of Biomedical Imaging and Bioengineering, the U.S. Department of Defence (DOD) , and the Bill and Melinda Gates Foundation, for the development of point of care diagnostics support the industry growth to great extent. Introduction of mobile applications such as cobas infinity point-of-care (Roche Diagnostics) , growing demand for point of care diagnostics, and rising investment by companies is expected to spur the growth in the coming years. However, the regulatory framework for approval process has been the most critical restraining factor for the industry growth.

    Complete Report is Available@ http://www.reportsweb.com/inquiry&RW00011433645/sample

    Products Takeaway
    In terms of products, the market is categorized as Glucose Testing, Hb1Ac Testing, Coagulation, Urinalysis, Fertility, Cardiac Markers, Infectious Diseases, Hematology, Decentralized Clinical Chemistry, Ambulatory Chemistry, Drug Abuse Testing, and others. Among which, glucose testing and Hb1Ac testing accounted for the largest share of the global market. Collectively, these segments achieved around USD 9.5 billion in 2017 and are anticipated to dominate the industry. However, cardiac markers segment is projected to grow with the highest growth rate over the forecast period.

    Disease Condition Takeaway
    Based on disease conditions, the market is broadly categorized into Human Immunodeficiency Virus (HIV) , Respiratory Syncytial, Human papillomavirus (HPV) , Clostridium difficile, Hepatitis B, Pneumonia, Influenza, Hepatitis C, Tuberculosis, and others. Use of molecular diagnostics for the treatment of HIV is rapidly increasing, accounting for the largest market. According to Canada’s Source for HIV and Hepatitis C information, the point of care diagnosis is a rapid testing technique for HIV patients that provides testing results in short time span, usually in an hour. In terms of end users, the market is distributed as Hospitals, Home, Laboratory Settings, and Others.

    Regional Takeaway
    Regionally the market is classified in North America, Europe, Asia Pacific and Rest of the world. Increasing population base with cardio metabolic disorders and diabetes is expected to stimulate the market growth in North America and Europe. According to the Centers for Disease Control and Prevention (CDC) , over 31% of population in the U.S. was suffering from bad cholesterol or LDL in 2012. On other side, large patient base coupled with the growing demand for in-vitro diagnostics in developing regions such as India and China provides a healthy platform for the POC growth in developing regions.

    Asia Pacific Point of care diagnostics market by Country, 2017 vs 2025

    Key Vendor Takeaway
    Companies such as Danaher Corporation, Roche Diagnostics, Alere Inc., bioMerieux, Abbott Laboratories, and Siemens Healthcare are profiled in the report. Strategic merger and acquisitions and the introduction of new products helped companies to capture significant revenue share. For example, Alere, Inc., one of the leader in rapid point of care diagnosis testing, hold strong distribution channel across the world in order to supply its products to laboratories, physicians’ clinics, and hospitals. This company also operates via third-party distributors for selling its products. Key distributor partners of the company include Henry Schein Medical, McKesson, NDC, Cardinal Health, Medline, Merck, Menearini Diagnostics, and Orion Diagnostica Oy.

    Inquiry for Report@ http://www.reportsweb.com/inquiry&RW00011433645/buying

    The market size and forecast for each segment has been provided for the period 2014 to 2025, considering 2015 as the base year. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2016 to 2025 for every reported segment.

    The years considered for the study are:
    Historical Year – 2014 & 2015
    Base Year – 2015
    Estimated Year – 2016
    Projected Year – 2025

    – TARGET AUDIENCE
    Traders, Distributors, And Suppliers
    Manufacturers
    Hospitals
    Government and Regional Agencies and Research Organizations
    Consultants
    Distributors

    SCOPE OF THE REPORT
    The scope of this report covers the market by its major segments, which include as follows:

    – MARKET, BY PRODUCT
    Glucose Testing
    Hb1Ac Testing
    Coagulation
    Urinalysis
    Fertility
    Cardiac Markers
    Infectious Diseases
    Hematology
    Decentralized Clinical Chemistry
    Ambulatory Chemistry
    Drug Abuse Testing
    Others

    – MARKET, BY DISEASE CONDITION
    Human Immunodeficiency Virus (HIV)
    Respiratory Syncytial
    Human papillomavirus (HPV)
    Clostridium difficile
    Hepatitis B
    Pneumonia
    Influenza
    Hepatitis C
    Tuberculosis
    Others

    – MARKET, BY REGION
    North America
    U.S.
    Canada
    Europe
    Germany
    France
    Rest of Europe
    Asia Pacific
    India
    China
    Rest of APAC
    Rest of the World
    Middle East and Africa
    Latin America

    Discount Inquiry@ http://www.reportsweb.com/inquiry&RW00011433645/discount


    Rajat Sahni
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

older | 1 | .... | 1030 | 1031 | (Page 1032) | 1033 | 1034 | .... | 1118 | newer